Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NLRP3 | Q96P20 | 3/20 | 0.46 |
| ▸ | IL1B | P01584 | 10/20 | 0.36 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.35 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.35 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.35 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.35 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.35 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.35 |
| ▸ | MAPK14 | Q16539 | 5/20 | 0.34 |
| ▸ | PIM1 | P11309 | 1/20 | 0.33 |
| ▸ | TNF | P01375 | 1/20 | 0.33 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25798600 | 0.91 | IL1B (0.41) | NLRP3IL1BTNF | |
| SCHEMBL25798590 | 0.89 | IL1B (0.44) | NLRP3IL1BPIM1TNF | |
| SCHEMBL25798535 | 0.86 | NLRP3 (0.55) | NLRP3IL1BMAPK14PIM1TNF | |
| SCHEMBL25798527 | 0.83 | NLRP3 (0.60) | NLRP3IL1BMAPK14 | |
| SCHEMBL25798595 | 0.83 | NLRP3 (0.46) | NLRP3IL1BMAPK14 | |
| SCHEMBL25798531 | 0.74 | IL1B (0.58) | NLRP3IL1BTNF | |
| SCHEMBL25797816 | 0.74 | IL1B (0.58) | NLRP3IL1BTNF | |
| SCHEMBL25798896 | 0.74 | NLRP3 (0.68) | NLRP3IL1BMAPK14 | |
| SCHEMBL25798598 | 0.74 | NLRP3 (0.42) | NLRP3IL1B | |
| SCHEMBL25798449 | 0.73 | NLRP3 (0.53) | NLRP3IL1BPSEN1PSEN2APH1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023129987-A1 | PYRIDAZINE DERIVATIVES AS MODULATORS OF NLRP3 INFLAMMASOME AND RELATED METHODS | Neumora Therapeutics, Inc. (US) | 2023-07-06 | — | — | WO | disclosed |